International Prescription Sourcing Update

November 20, 2026

We are actively monitoring the evolving requirements surrounding international prescription sourcing and remain encouraged by our international pharmacy partner's readiness.

Importantly, the FDA's underlying personal importation policy has not changed. The primary change involves increased customs reporting, disclosure requirements, and visibility into international prescription shipments, rather than a new FDA prohibition on personal importation.

U.S. Customs and Border Protection (CBP) recently extended the implementation deadline for its new electronic filing requirements from October 22, 2026, to January 20, 2027, allowing additional time for compliance preparations.

MotivHealth is taking several proactive steps:

- **Pharmacy partner readiness:** We are working closely with our international pharmacy partner, who has expressed confidence in its ability to meet the evolving reporting and compliance requirements.
- **Program continuity:** We are coordinating with our partner to preserve member access and minimize potential disruption.
- **Alternative sourcing:** We continue evaluating domestic and other pharmacy savings solutions to ensure long-term program sustainability.

While increased scrutiny introduces some uncertainty, we are encouraged by our partner's preparations and remain committed to maintaining member access and delivering meaningful pharmacy savings.

As new information becomes available, we'll share what's changing and what it means for our clients and members.